Patents by Inventor Soumojeet Ghosh
Soumojeet Ghosh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160136099Abstract: The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The invention further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed composition, wherein the pre-shaped bodies are interconnected by flash.Type: ApplicationFiled: January 21, 2016Publication date: May 19, 2016Inventors: Soumojeet Ghosh, Didier Lefebvre, Bryan Wiesner, Kevin Novak, Thomas Kessler
-
Patent number: 9278052Abstract: The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The invention further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed composition, wherein the pre-shaped bodies are interconnected by flash.Type: GrantFiled: November 4, 2011Date of Patent: March 8, 2016Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KGInventors: Soumojeet Ghosh, Didier Lefebvre, Bryan Wiesner, Kevin Novak, Thomas Kessler
-
Patent number: 8895051Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.Type: GrantFiled: May 10, 2013Date of Patent: November 25, 2014Inventors: Laman Alani, Donald P. Gauwitz, Dilip Kaul, John M. Lipari, Soumojeet Ghosh, Kennan C. Marsh, Richard H. Whelan, Vanik D. Petrossian
-
Publication number: 20140179721Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 5° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: February 26, 2014Publication date: June 26, 2014Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8691878Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: November 12, 2012Date of Patent: April 8, 2014Assignee: AbbVie Inc.Inventors: Jeorg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Publication number: 20130252985Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.Type: ApplicationFiled: May 10, 2013Publication date: September 26, 2013Inventors: Laman Alani, Donald P. Gauwitz, Dilip Kaul, John M. Lipari, Soumojeet Ghosh, Kennan C. Marsh
-
Patent number: 8501219Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.Type: GrantFiled: January 14, 2010Date of Patent: August 6, 2013Assignee: AbbVie Inc.Inventors: Laman Alani, Donald P. Gauwitz, Dilip Kaul, John M. Lipari, Soumojeet Ghosh, Kennan C. Marsh, Richard H. Whelan, Vanik D. Petrossian
-
Patent number: 8486983Abstract: A liquid formulation for oral administration of the CETP inhibitor of formula (I) has improved bioavailability compared with conventional solid formulations. The formulation comprises the CETP inhibitor, or a pharmaceutically acceptable salt thereof; an oil; and one or more nonionic surfactants having a hydrophilic lipophilic balance (HLB)>10.Type: GrantFiled: December 5, 2006Date of Patent: July 16, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Agam R. Sheth, Bhagwant Rege, Soumojeet Ghosh, Laman L. Alani, Maria T. Cruanes, Craig A. McKelvey
-
Patent number: 8414921Abstract: Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.Type: GrantFiled: December 12, 2006Date of Patent: April 9, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Ashkan Kamali, Laman Alani, Kyle A. Fliszar, Soumojeet Ghosh, Monica Tijerina
-
Patent number: 8399015Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: September 22, 2011Date of Patent: March 19, 2013Assignee: AbbVie Inc.Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8377952Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, to a pharmaceutical dosage formulation comprising an HIV protease inhibitor.Type: GrantFiled: February 23, 2005Date of Patent: February 19, 2013Assignee: Abbott LaboratoriesInventors: Jöerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman L. Alani, Soumojeet Ghosh
-
Publication number: 20130004578Abstract: The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor.Type: ApplicationFiled: September 10, 2012Publication date: January 3, 2013Applicant: ABBVIE INC.Inventors: Jörg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8333990Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: September 13, 2010Date of Patent: December 18, 2012Assignee: Abbott LaboratoriesInventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8309613Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: September 13, 2010Date of Patent: November 13, 2012Assignee: AbbVie Inc.Inventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Patent number: 8268349Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: April 18, 2012Date of Patent: September 18, 2012Assignee: Abbott LaboratoriesInventors: Joerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Joerg Breitenbach, Laman Alani, Soumojeet Ghosh
-
Publication number: 20120205830Abstract: The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The invention further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed composition, wherein the pre-shaped bodies are interconnected by flash.Type: ApplicationFiled: November 4, 2011Publication date: August 16, 2012Inventors: Soumojeet Ghosh, Didier Lefebvre, Bryan Wiesner, Kevin Novak, Thomas Kessler
-
Publication number: 20120202838Abstract: In one embodiment, the present invention relates to abuse-deterrent drug formulations comprise a plurality of discrete domains uniformly dispersed in a pharmaceutically acceptable matrix, wherein said domains have high fracture toughness and comprise at least one polymer and at least one abuse-relevant drug. In another embodiment, the present invention relates to a formulation comprising a plurality of discrete mechanically reinforcing particles uniformly dispersed in a pharmaceutically acceptable matrix, wherein said matrix has high fracture toughness and comprises at least one polymer and at least one active agent, at least one abuse-relevant drug or a combination of at least one active agent and at least one abuse-relevant drug.Type: ApplicationFiled: November 4, 2011Publication date: August 9, 2012Applicants: Abbott Laboratories, Abbott GmbH & Co. KGInventors: Soumojeet Ghosh, Didier Lefebvre, Bryan Wiesner, Joerg Breitenbach
-
Publication number: 20120202858Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: April 18, 2012Publication date: August 9, 2012Applicant: ABBOTT LABORATORIESInventors: Jöerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman L. Alani, Soumojeet Ghosh
-
Publication number: 20120022089Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: ApplicationFiled: September 22, 2011Publication date: January 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jöerg Rosenberg, Ulrich Reinhold, Bernd Liepold, Gunther Berndl, Jörg Breitenbach, Laman L. Alani, Soumojeet Ghosh
-
Patent number: 8025899Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.Type: GrantFiled: August 25, 2004Date of Patent: September 27, 2011Assignee: Abbott LaboratoriesInventors: Gunther Berndl, Joerg Rosenberg, Bernd Liepold, Joerg Breitenbach, Ulrich Reinhold, Laman Alani, Soumojeet Ghosh